Boston Scientific Corporation $BSX Shares Bought by Machina Capital S.A.S.

Machina Capital S.A.S. grew its position in shares of Boston Scientific Corporation (NYSE:BSX) by 119.4% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 52,194 shares of the medical equipment provider’s stock after buying an additional 28,401 shares during the quarter. Boston Scientific accounts for 0.9% of Machina Capital S.A.S.’s investment portfolio, making the stock its 19th largest holding. Machina Capital S.A.S.’s holdings in Boston Scientific were worth $5,096,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in BSX. Riverwater Partners LLC boosted its holdings in Boston Scientific by 3.3% in the 2nd quarter. Riverwater Partners LLC now owns 3,104 shares of the medical equipment provider’s stock valued at $333,000 after purchasing an additional 98 shares in the last quarter. Gerber Kawasaki Wealth & Investment Management raised its stake in shares of Boston Scientific by 3.8% during the 2nd quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider’s stock worth $291,000 after buying an additional 99 shares in the last quarter. Crown Wealth Group LLC lifted its holdings in shares of Boston Scientific by 4.7% in the 3rd quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider’s stock valued at $218,000 after buying an additional 100 shares during the period. Sound View Wealth Advisors Group LLC boosted its stake in shares of Boston Scientific by 3.9% in the second quarter. Sound View Wealth Advisors Group LLC now owns 2,738 shares of the medical equipment provider’s stock valued at $294,000 after buying an additional 103 shares in the last quarter. Finally, Scotia Capital Inc. boosted its stake in shares of Boston Scientific by 0.7% in the second quarter. Scotia Capital Inc. now owns 15,093 shares of the medical equipment provider’s stock valued at $1,621,000 after buying an additional 104 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insiders Place Their Bets

In other news, Director Ellen M. Zane sold 12,891 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the transaction, the director directly owned 24,134 shares of the company’s stock, valued at $2,371,889.52. This trade represents a 34.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the transaction, the executive vice president owned 23,600 shares of the company’s stock, valued at $2,396,580. This represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 191,105 shares of company stock worth $18,067,697. Insiders own 0.50% of the company’s stock.

Wall Street Analyst Weigh In

BSX has been the topic of a number of recent analyst reports. Needham & Company LLC reaffirmed a “buy” rating on shares of Boston Scientific in a report on Thursday, January 15th. Citigroup restated a “buy” rating on shares of Boston Scientific in a research report on Wednesday, January 14th. Truist Financial cut their price target on shares of Boston Scientific from $130.00 to $120.00 and set a “buy” rating for the company in a report on Thursday, December 18th. Barclays reduced their price objective on shares of Boston Scientific from $136.00 to $124.00 and set an “overweight” rating for the company in a research note on Tuesday. Finally, Wells Fargo & Company boosted their price objective on shares of Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $123.26.

Boston Scientific Trading Down 0.3%

NYSE:BSX opened at $91.56 on Wednesday. Boston Scientific Corporation has a 52-week low of $85.98 and a 52-week high of $109.50. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. The stock has a fifty day simple moving average of $94.89 and a 200-day simple moving average of $99.29. The company has a market capitalization of $135.73 billion, a PE ratio of 48.96, a price-to-earnings-growth ratio of 1.63 and a beta of 0.67.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.